Amaç: Obez gebelerde ilk trimester serum inflamatuvar markerlarını sağlıklı gebeler ile karşılaştırmak ve bu markerların gebelik ile neonatal sonuçları öngörmesini incelemek
Metod: Bu çalışma, prospektif bir gözlemsel çalışma olup çalışma grubuna 46 obez gebe ile kontrol grubu ise sağlıklı 60 gebeden oluşturulmuştur. Katılımcıların demografik özellikleri, obstetrik ve neonatal sonuçları değerlendirilmiş olup nötrofil-lenfosit oranı (NLR), ile sistemik inflamasyon indeks (SII: NLR*platelet sayısı), sistemik inflamasyon response indeks (SIRI: NLR*monosit sayısı), sistemik inflamasyon agregat indeksi (AISI: NLR* platelet sayısı * monosit sayısı), PLR (platelet-lenfosit oranı) hesaplanmıştır. Yenidoğan yoğun bakım ihtiyacı (NICU) ve kötü obstetrik sonuçlaro öngörmeyi değerlendirmek için Alıcı İşletim Karakteristiği (ROC) eğrileri oluşturuldu ve eğri altındaki alan değerleri standart yöntemler kullanılarak hesaplandı.
Bulgular: Her iki grubunda demografik özellikleri benzerdi. Çalışma grubunda acil sezaryan, kötü obstetrik sonuç ve NICU ihtiyacı fazlaydı. Obez grupta inflamatuvar marker olan beyaz kan hücre sayımı ile nötrofil ve monosit, platelet sayımı yüksek bulundu. Ayrıca maternal obez grupta SII, SIRI, AISI, NLR istatistiksel anlamlı yüksekti. Ayrıca, PLR ise çalışma grubunda kontrol grubuna göre bulundu. ROC analizinde, obez gebelerde kötü obstetrik sonuçları öngörme kapasitesinin SII ve AISI için istatistiksel olarak anlamlı olduğu görüldü.
Sonuç: Maternal obezitede neonatal ve obstetrik sonuçları öngörmede SII, SIRI, AISI, PLR ve NLR yardımcı olabilir.
Aims: To compare first trimester serum inflammatory markers in obese pregnant women with healthy pregnant women and to investigate the predictive value of these markers for pregnancy and neonatal outcomes
Methods: This prospective observational study included 46 pregnant women with maternal obesity and 60 healthy pregnant women without obesity. The demographic characteristics, obstetric and neonatal outcomes of the participants were evaluated, and the neutrophil-lymphocyte ratio (NLR), systemic inflammation index (SII: NLR*platelet), systemic inflammation response index (SIRI: NLR*monocyte), aggregate index of systemic inflammation (AISI: NLR*platelet count*monocyte), and PLR (platelet-lymphocyte ratio) were calculated. To evaluate the predictive value for neonatal intensive care unit (NICU) admission and adverse obstetric outcomes, receiver operating characteristic curves were generated and the area under the curve values were calculated.
Results: The demographic characteristics of both groups were similar. In the study group, adverse obstetric outcomes, and NICU requirement were increased. In the maternal obese group, inflammatory markers such as SII, SIRI, AISI, and NLR were significantly elevated. PLR was also increased in the study group. In ROC analysis, it was found that the levels of inflammatory markers to predict adverse obstetric and neonatal outcomes in obese pregnant women were statistically significant.
Conclusion: SII, SIRI, AISI, PLR, and NLR may be helpful in predicting neonatal and obstetric outcomes in maternal obesity.
Ethical approval was obtained from the Ethics Committee of the Ministry of Health Ankara Bilkent City Hospital (TABED 2-24-642). This study complies with the Declaration of Helsinki. Written and oral informed consent was obtained from all participants.
None
The authors would like to thank all healthcare professionals who are dedicated to combating obesity and maternal-fetal health disorders, and to protecting the well-being of mothers and infants. This study received no financial support. The data supporting the findings of this study are available from the corresponding author (BAA) upon reasonable request.
| Primary Language | English |
|---|---|
| Subjects | Obstetrics and Gynaecology |
| Journal Section | Original Article |
| Authors | |
| Publication Date | October 25, 2025 |
| Submission Date | September 14, 2025 |
| Acceptance Date | October 11, 2025 |
| Published in Issue | Year 2025 Volume: 8 Issue: 6 |
Interuniversity Board (UAK) Equivalency: Article published in Ulakbim TR Index journal [10 POINTS], and Article published in other (excuding 1a, b, c) international indexed journal (1d) [5 POINTS].
The Directories (indexes) and Platforms we are included in are at the bottom of the page.
Note: Our journal is not WOS indexed and therefore is not classified as Q.
You can download Council of Higher Education (CoHG) [Yüksek Öğretim Kurumu (YÖK)] Criteria) decisions about predatory/questionable journals and the author's clarification text and journal charge policy from your browser. https://dergipark.org.tr/tr/journal/2316/file/4905/show
The indexes of the journal are ULAKBİM TR Dizin, Index Copernicus, ICI World of Journals, DOAJ, Directory of Research Journals Indexing (DRJI), General Impact Factor, ASOS Index, WorldCat (OCLC), MIAR, EuroPub, OpenAIRE, Türkiye Citation Index, Türk Medline Index, InfoBase Index, Scilit, etc.
The platforms of the journal are Google Scholar, CrossRef (DOI), ResearchBib, Open Access, COPE, ICMJE, NCBI, ORCID, Creative Commons, etc.
| ||
|
Our Journal using the DergiPark system indexed are;
Ulakbim TR Dizin, Index Copernicus, ICI World of Journals, Directory of Research Journals Indexing (DRJI), General Impact Factor, ASOS Index, OpenAIRE, MIAR, EuroPub, WorldCat (OCLC), DOAJ, Türkiye Citation Index, Türk Medline Index, InfoBase Index
Our Journal using the DergiPark system platforms are;
Journal articles are evaluated as "Double-Blind Peer Review".
Our journal has adopted the Open Access Policy and articles in JHSM are Open Access and fully comply with Open Access instructions. All articles in the system can be accessed and read without a journal user. https//dergipark.org.tr/tr/pub/jhsm/page/9535
Journal charge policy https://dergipark.org.tr/tr/pub/jhsm/page/10912
Our journal has been indexed in DOAJ as of May 18, 2020.
Our journal has been indexed in TR-Dizin as of March 12, 2021.
Articles published in the Journal of Health Sciences and Medicine have open access and are licensed under the Creative Commons CC BY-NC-ND 4.0 International License.